Pipeline

In-house R&D projects open for out-licensing and/or co-development partnerships:

Pharmahungary Group runs in-house R&D projects for the development of therapies in cardiovascular and metabolic diseases up to phase II clinical stage. Investors and co-development partners are welcome:

• ProtectomiR: (www.protectomir.com): identification of cytoprotective miRNA-s, i.e. „protectomiRs” (IP protected, primary filing Oct, 2011)

The following in-house diagnostic R&D projects of Pharmahungary Group are in the early clinical phase of development:

• Infarnosys: (www.infarnosys.com): novel biomarker diagnostic system for the assessment of the prognosis of acute myocardial ischemia/reperfusion injury and infarction and the effectiveness of the treatment. SME Instrument Phase I winner project.
• Vezics: (www.vezics.com): modular and scalable chromatography platform for high-quality exosome isolation for biomarker and therapy. SME Instrument Phase I winner project.

Pharmahungary Group bioinformatics tools are already available online:

• miRNAtarget: (www.mirnatarget.com): bioinformatics project for target prediction: miRNA targets.
• Vigilace: (www.vigilace.com): bioinformatics project for prediction and determination of previously unknown adverse events and drug interactions.
• InfarctSizeAI: (www.infarctsize.com): automatic, Artificial Intelligence assisted analysis of infarct regions and sizes on stained small and large animal heart images.